Clinical Trial Details
| Trial ID: | L0617 |
| Source ID: | NCT00121602 |
| Associated Drug: | Darbepoetin Alfa |
| Title: | Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Anemia|Kidney Disease |
| Interventions: | DRUG: Darbepoetin Alfa |
| Outcome Measures: | Primary: Change in Hb level between the screening/baseline period and the evaluation period, 30 weeks|The ratio of weekly dosing requirements between baseline and the evaluation period, 28 weeks | Secondary: Change from baseline Hb over time, 29 weeks|Proportion of subjects maintaining mean Hb within target range during evaluation period, 7 weeks|Average darbepoetin alfa dose over evaluation period, 7 weeks|Change from baseline dose over time, 29 weeks |
| Sponsor/Collaborators: | Sponsor: Amgen |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 446 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT |
| Start Date: | 2005-03 |
| Completion Date: | 2006-10 |
| Results First Posted: | |
| Last Update Posted: | 2008-02-28 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00121602 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|